Zobrazeno 1 - 10
of 245
pro vyhledávání: '"JAK2‐V617F"'
Autor:
Tobias Ronny Haage, Emmanouil Charakopoulos, Vikas Bhuria, Conny K. Baldauf, Mark Korthals, Juliane Handschuh, Peter Müller, Juan Li, Kunjan Harit, Gopala Nishanth, Stephanie Frey, Martin Böttcher, Klaus-Dieter Fischer, Jan Dudeck, Anne Dudeck, Daniel B. Lipka, Burkhart Schraven, Anthony R. Green, Andreas J. Müller, Dimitrios Mougiakakos, Thomas Fischer
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-23 (2024)
Abstract Background Neutrophils play a crucial role in inflammation and in the increased thrombotic risk in myeloproliferative neoplasms (MPNs). We have investigated how neutrophil-specific expression of JAK2-V617F or CALRdel re-programs the function
Externí odkaz:
https://doaj.org/article/de0cb7b1744d4527b1c4f8287f2223f4
Autor:
Vikas Bhuria, Tobias Franz, Conny Baldauf, Martin Böttcher, Nicolas Chatain, Steffen Koschmieder, Tim H. Brümmendorf, Dimitrios Mougiakakos, Burkhart Schraven, Sascha Kahlfuß, Thomas Fischer
Publikováno v:
Cell Communication and Signaling, Vol 22, Iss 1, Pp 1-22 (2024)
Abstract Background Calcium (Ca2+) signaling regulates various vital cellular functions, including integrin activation and cell migration. Store-operated calcium entry (SOCE) via calcium release-activated calcium (CRAC) channels represents a major pa
Externí odkaz:
https://doaj.org/article/db493b9498e045b9a9db0c8fc03508d6
Autor:
Sivahari Prasad Gorantla, Tony Andreas Mueller, Corinna Albers‐Leischner, Martina Rudelius, Nikolas vonBubnoff, Justus Duyster
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 415-430 (2024)
Tyrosine‐protein kinase (janus kinase; JAK)–signal transducer and activator of transcription (STAT) signaling plays a pivotal role in the development of myeloproliferative neoplasms (MPNs). Treatment with the potent JAK1/JAK2‐specific inhibitor
Externí odkaz:
https://doaj.org/article/7d73443b165c4267b410f643f968e47e
Autor:
Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis. Ruxolitinib will remain a main stay in the treatment of MPN patients due to its effective the
Externí odkaz:
https://doaj.org/article/d15f0a582d1444fa955de4dbeaac8a8c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jasmin Regensburger, Teresa Rauchegger, Lorin Loacker, Florian Falkner, Clemens Feistritzer, Barbara Teuchner
Publikováno v:
BMC Ophthalmology, Vol 22, Iss 1, Pp 1-6 (2022)
Abstract Background Polycythemia vera (PV) is a myeloproliferative neoplasm with increased hemoglobin, hematocrit, platelet count and leukocytosis, resulting in increased blood viscosity. PV which is initially presenting with ocular symptoms is rare,
Externí odkaz:
https://doaj.org/article/2d7ca5e775f24d2ebca520c76c34c3e3
Autor:
Hrvoje Holik, Ivan Krečak, Marko Lucijanić, Ivan Samardžić, Danijel Pilipac, Ivana Vučinić Ljubičić, Božena Coha, Alma Kitter Pipić, Blaženka Miškić, Silva Zupančić-Šalek
Publikováno v:
Life, Vol 13, Iss 6, p 1388 (2023)
Background: Osteoarthritis (OA) is a progressive degenerative disease with an inflammatory background. Chronic myeloproliferative neoplasms (MPN) are clonal hematopoietic disorders characterized by chronic inflammation and a tendency for connective t
Externí odkaz:
https://doaj.org/article/be95d397d432430eabfcfc704c41c122
Autor:
Nicola Padzik, Małgorzata Szewczuk
Publikováno v:
Roczniki Naukowe Polskiego Towarzystwa Zootechnicznego, Vol 17, Iss 1, Pp 13-21 (2021)
A potential cause of essential thrombocythaemia can be seen as the V617F point mutation within Janus kinase 2. This mutation occurs in 60-70% of patients with this disease and is located in the domain acting as an inhibitor. It increases the enzymati
Externí odkaz:
https://doaj.org/article/9e1699cfd2e84ec78f01867596a1f248
Publikováno v:
Molecular Cytogenetics, Vol 13, Iss 1, Pp 1-7 (2020)
Abstract Background To explore the clinical features of the patients with BCR-ABL1-negative chronic myeloproliferative neoplasms (MPNs) in our hospital and to reveal the unique features of BCR-ABL1-negative MPNs patients in our center. Methods Retros
Externí odkaz:
https://doaj.org/article/a487e841e338481f805463a0615346e0